|
|
|
|
|
|
|
|
|
|
|
08.12.25 - 14:36
|
Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump (24/7 Wall St.)
|
|
|
Abbott Laboratories (NYSE: ABT) and Eli Lilly (NYSE: LLY) just reported Q3 earnings that highlight two fundamentally different healthcare bets. Abbott delivered steady 6.9% revenue growth anchored by medical devices. Lilly posted explosive 54% revenue growth powered by its GLP-1 obesity and diabetes drugs. Medical Devices Carry Abbott. GLP-1s Carry Lilly. Abbott's medical device segment ... Lilly's GLP-1 Surge Dwarfs Abbott's Steady Device Growth With 54% Revenue Jump
The post Lilly's GLP-1 Surge Dwarfs Abbott's Steady Device Growth With 54% Revenue Jump appeared first on 24/7 Wall St.....
|
|
|
05.11.25 - 11:48
|
Ozempic maker Novo Nordisk cuts sales and profit forecasts again (The Guardian)
|
|
|
Downgrade comes as Danish company continues to lose ground to Mounjaro firm Eli Lilly in weight-loss drug marketThe maker of the weight-loss drugs Ozempic and Wegovy has cut its sales and profit forecasts as it continues to fall behind in the competitive market for obesity and diabetes treatments.Novo Nordisk's chief executive, Mike Doustdar, who took the reins in August, said the reduced guidance was because of “the lower growth expectations for our GLP-1 treatments”. Continue reading......
|
|
|
05.11.25 - 08:12
|
Novo Cuts Outlook Citing Lower Wegovy, Ozempic Sales (Bloomberg)
|
|
|
Novo Nordisk A/S pared its forecast for a fourth time this year, citing lower-than-anticipated sales of its blockbuster drugs Wegovy and Ozempic. The Danish drugmaker is struggling to compete with Eli Lilly & Co. in the growing market for obesity medicines. Bloomberg's Sara Sjolin reports....
|
|
|
30.10.25 - 15:15
|
ROUNDUP: Lilly hebt nach überraschend gutem Quartal Jahresausblick erneut an (DPA-AFX)
|
|
|
Der US-Pharmakonzern Lilly profitiert weiterhin von einem starken Lauf bei seinen Diabetesmitteln und Gewichtssenkern Mounjaro und Zepbound. Im dritten Quartal konnten die Amerikaner die durchschnittlichen Erwartungen von Analysten übertrumpfen. Konzernchef David Ricks hob daher zur Zahlenvorlage ein weiteres Mal seine Ziele für das Jahr an. Die Aktie kletterte am Donnerstag nach Handelsstart um knapp zwei Prozent nach oben..
|
|
|
30.10.25 - 14:54
|
Eli Lilly Blows Away Q3 Earnings Expectations (24/7 Wall St.)
|
|
|
Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded expectations while raising full-year guidance. The stock traded at $854.08 following the pre-market release, reflecting investor confidence in the company's accelerating momentum across its core portfolio. Incretin Dominance Reshapes the Quarter Lilly's incretin drugs drove the earnings beat. Mounjaro, ... Eli Lilly Blows Away Q3 Earnings Expectations
The post Eli Lilly Blows Away Q3 Earnings Expectations appeared first on 24/7 Wall St.....
|
|
|
|
|
30.10.25 - 12:30
|
ROUNDUP: Eli Lilly Again Boosts FY25 Outlook (AFX)
|
|
|
INDIANAPOLIS (dpa-AFX) - While reporting financial results for the third quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the ......
|
|
|
|
|
|
|
|
|
|
|
|
|
17.10.25 - 10:18
|
Novo Nordisk und Eli Lilly unter Druck – Trump will massiven Preissturz (Der Aktionaer)
|
|
|
Die Aktien von Novo Nordisk und Eli Lilly stehen zum Wochenschluss deutlich unter Druck. Knapp vier beziehungsweise gut vier Prozent geht es bei den Werten auf der Handelsplattform Tradegate am Freitagvormittag nach unten. Auslöser waren Aussagen von US-Präsident Trump, der Preissenkungen für Abnehmmedikamente in Aussicht stellte....
|
|
|
|
|
|
|
18.09.25 - 12:36
|
Novo Nordisk shares shoot up amid promising results for anti-obesity pill (The Guardian)
|
|
|
Stock climbs above £6.5bn in early trading as trial shows 'significant weight loss' for pill version of WegovyBusiness live – latest updatesThe value of the drugmaker Novo Nordisk has shot up by more than £6.5bn after research showed its new anti-obesity pill resulted in almost as much weight loss as its Wegovy jab, as it races against its US rival Eli Lilly to get a tablet treatment to market.Stock in the Danish company climbed by more than 4.5% on Thursday morning on hopes it could claw back market share lost to Eli Lilly and cheaper generic versions of GLP-1 drugs. Shares have fallen nearly 60% in the past year as sales slowed. Continue reading......
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
